2 results match your criteria: "Stephenson Cancer Center and the University of Oklahoma Health Sciences Center[Affiliation]"
Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model.
Oncologist
July 2024
Section of Hematology/Oncology, Department of Medicine, Stephenson Cancer Center and the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Prescription drug costs within oncology remain a challenge for many patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, aiming to provide transparently priced medications at reduced costs. In this study, we sought to describe the potential impact of MCCPDC on Medicare Part-D oncology spending related to cancer-directed (n = 7) and supportive care (n = 26) drugs.
View Article and Find Full Text PDFHealth Disparities in Cancer Among American Indians and Alaska Natives.
Acad Radiol
July 2022
Department of Internal Medicine, Stephenson Cancer Center and the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
American Indians and Alaska Natives (AI/AN) are underserved populations who suffer from several health disparities, 1 of which is cancer. Malignancies, especially cancers of the breast, liver, and lung, are common causes of death in this population. Health care disparities in this population include more limited access to diagnostic radiology because of geographic and/or health system limitations.
View Article and Find Full Text PDF